Vofo BN, Beykin G, Levy J, et al. - In the present study, the researchers sought to assess the long-term functional and anatomical outcomes of neovascular age-related macular degeneration (nvAMD) treated with intravitreal anti-vascular endothelial growth factor (anti-VEGF) for up to 10 years, as well as identify associated risk factors. From 276 eligible eyes in 206 patients, 80 eyes (29%) in 66 patients (32.0%) had a follow-up period of ≥ 8 years and were involved in this investigation. Patients with nvAMD who underwent anti-VEGF therapy for 10 years experienced significant vision loss, which was associated with the presence of intraretinal fluid at baseline and macular atrophy. Major risk alleles for AMD in two complement genes were linked to a slower reduction in macular thickness over time.